Abstract 499P
Background
EGFR mutations occur in about half of the advanced non-squamous NSCLC patients in East Asia. Majority of the common activating mutations like L858R, exon 19 deletions (del) and T790M are detected by hot spot test methods in Hong Kong. However, hot spot test may not detect other uncommon EGFR alterations like point mutations, exon 20 insertions and amplifications, in which the best treatment remains undefined. Using a comprehensive liquid biopsy we investigated the prevalence of these uncommon EGFR alterations in ctDNA from NSCLC patients.
Methods
All Guardant360 (Guardant Health, Redwood City, CA) requests ordered in Hong Kong between Jan 2016 and June 2019 were reviewed. This is a next-generation ctDNA sequencing (NGS) panel of 74 cancer-related genes, including complete exon sequencing of EGFR. We identified cases with a diagnosis of “lung cancer” and excluded pure squamous, small cell, neuroendocrine and sarcomatoid histology. Uncommon EGFR alterations, defined as amplification or mutations other than L858R, exon 19 del, or T790M were identified. Synonymous mutations and variants of unknown significance were excluded. Demographics and impact of results to subsequent management will be analyzed and presented later.
Results
A total of 282 non-squamous NSCLC patients were tested. Samples came from 146 women and 136 men, with a median age 60. ctDNA was identified in 241 samples (85.5% detection rate). EGFR alterations were identified in 95 samples (39.4%), including L858R (48), exon 19 del (27), and T790M (24). Uncommon alterations were found in 47 of 95 EGFR cases (49.5%); 18 of these had no co-existing common EGFR or other driver mutation. These included amplifications (8); exon 20 insertions (8); L861Q (2); and other point mutations (4); 4 cases had an uncommon mutation with amplification.
Conclusions
Using a comprehensive ctDNA NGS panel, 47 out of 241 (19.5%) non-squamous NSCLC patients with uncommon EGFR alterations were detected. Novel NGS methods can help identify this group of patients with unmet needs for a gene-directed therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guardant Health AMEA.
Funding
Has not received any funding.
Disclosure
O.S.H. Chan: Full / Part-time employment: Hong Kong Integrated Oncology Centre; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Merck Sharp & Dohme. G.Y. Cheung: Full / Part-time employment: Sanomics Limited. M.M.L. Lee: Full / Part-time employment: Guardant Health AMEA. S. Olsen: Full / Part-time employment: Guardant Health AMEA; Shareholder / Stockholder / Stock options: Guardant Health Inc; Shareholder / Stockholder / Stock options: AstraZeneca.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract